RhumbLine Advisers
CMMB

RhumbLine Advisers’s Chemomab Therapeutics CMMB Stock Holding History

RhumbLine Advisers’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.5K Buy
30,529
+12,163
+66% +$20.5K ﹤0.01% 3685
2026
Q1 		$28.8K Buy
18,366
+510
+3% +$871 ﹤0.01% 3677
2025
Q4 		$29.5K Buy
17,856
+8,351
+88% +$22.2K ﹤0.01% 3719
2025
Q3 		$25K Sell
9,505
-464
-5% -$1.71K ﹤0.01% 3751
2025
Q2 		$46.2K Buy
9,969
+4,007
+67% +$19.8K ﹤0.01% 3677
2025
Q1 		$26K Buy
5,962
+10
+0.2% +$70 ﹤0.01% 3697
2024
Q4 		$43.1K Sell
5,952
-941
-14% -$5.94K ﹤0.01% 3682
2024
Q3 		$43.3K Buy
6,893
+1,924
+39% +$10.8K ﹤0.01% 3701
2024
Q2 		$18.3K Buy
4,969
+312
+7% +$1.08K ﹤0.01% 3885
2024
Q1 		$14.5K Hold
4,657
– – ﹤0.01% 3810
2023
Q4 		$9.5K Buy
4,657
+3,946
+555% +$10.4K ﹤0.01% 3870
2023
Q3 		$2.54K Sell
711
-40
-5% -$187 ﹤0.01% 4089
2023
Q2 		$3.94K Buy
+751
New +$4.74K ﹤0.01% 4123

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's CMMB Position: Q2 2026 in Review

RhumbLine Advisers increased its Chemomab Therapeutics (CMMB) stake by 66% in Q2 2026, buying an estimated $20.5K and bringing the position to 30,529 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3685.

RhumbLine Advisers first reported a position in CMMB in Q2 2023 and has held it in 13 quarters since. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • RhumbLine Advisers held 30,529 shares of Chemomab Therapeutics worth $49.5K as of Q2 2026.
  • RhumbLine Advisers bought 12,163 Chemomab Therapeutics shares in Q2 2026, an estimated $20.5K.
  • Chemomab Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3685 holding.
  • RhumbLine Advisers first reported a position in Chemomab Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.